Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology: Profitable, Troubled, But Worth A Good Look (NASDAQ:PBYI) | Seeking Alpha
Dennis Sanders - Senior Clinical Specialist - Puma Biotechnology, Inc. | LinkedIn
PBYI Stock Price and Chart — NASDAQ:PBYI — TradingView
Puma Biotechnology
Puma Inc 2024 | www.favors.com
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor | Business Wire
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | citybiz
Puma Biotech agrees to pay investors $54.2 mln in fraud case | Reuters
Puma Biotechnology Surging
Puma Biotech In-Licenses Takeda's Cancer Candidate With Primary Focus On Breast & Lung Cancer
Strength Seen in Puma Biotech (PBYI): Can Its 10.0% Jump Turn into More Strength?
Puma Biotechnology falls more than 20%
Puma Biotechnology unveils Phase II breast cancer trial design